P1432: PATTERNS OF VOXELOTOR USE IN A MULTICENTER, REAL-WORLD STUDY OF PATIENTS WITH SICKLE CELL DISEASE

Bibliographic Details
Published in:	HemaSphere
Main Authors:	Biree Andemariam, Modupe Idowu, Nirmish Shah, Richard Drachtman, Archana Sharma, Alexander Glaros, Maureen Achebe, Alecia Nero, Brooke Hayward, Michelle Xu, Susanna Curtis
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000972612.13942.6f

Similar Items

5559749 A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
by: B. Andemariam, et al.
Published: (2023-04-01)

P1485: A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
by: B. Andemariam, et al.
Published: (2022-06-01)

PB2516: ACTIGRAPHY IMPROVEMENT WITH VOXELOTOR (ACTIVE) STUDY: IMPACT OF VOXELOTOR ON PHYSICAL ACTIVITY, FATIGUE, AND SLEEP QUALITY
by: Nirmish Shah, et al.
Published: (2023-08-01)

PADRÕES DE USO DE VOXELOTOR EM UM ESTUDO MULTICÊNTRICO DO MUNDO REAL DE PACIENTES COM DOENÇA FALCIFORME
by: B Andemariam, et al.
Published: (2023-10-01)

Voxelotor (GBT440) in pediatric sickle cell disease: A review
by: Sri Lakshmi Jamalapur, et al.
Published: (2024-12-01)

Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease
by: Barriteau CM, et al.
Published: (2022-11-01)

Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action
by: Mohd. Suhail
Published: (2024-01-01)

P1450: VOXELOTOR TREATMENT LEADS TO IMPROVED VIABILITY OF SICKLE ERYTHROCYTES
by: Kadère Konté, et al.
Published: (2023-08-01)

5579775 OVERVIEW OF THE VOXELOTOR POST-APPROVAL CLINICAL RESEARCH PROGRAM
by: C. Minniti, et al.
Published: (2023-04-01)

5610357 REDUCTION IN BLOOD TRANSFUSION BURDEN FOLLOWING INITIATION OF VOXELOTOR OR CRIZANLIZUMAB: A CASE SERIES
by: A. Baruwa Etti, et al.
Published: (2023-04-01)

GBT1118, a Voxelotor Analog, Ameliorates Hepatopathy in Sickle Cell Disease
by: Elio Haroun, et al.
Published: (2024-09-01)

Modeling the public health impact of voxelotor in the management of sickle cell disease in France.
by: Frédéric Galacteros, et al.
Published: (2023-01-01)

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease
by: Paul Telfer, et al.
Published: (2018-05-01)

Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma
by: Radojka M. Savic, et al.
Published: (2022-06-01)

Patient Controlled Analgesia for Adults with Sickle Cell Disease Awaiting Admission from the Emergency Department
by: Josue Santos, et al.
Published: (2016-01-01)

S118: LONG-TERM SAFETY AND EFFICACY OF VOXELOTOR FOR PATIENTS WITH SICKLE CELL DISEASE: RESULTS FROM AN OPEN-LABEL EXTENSION OF THE PHASE 3 HOPE TRIAL
by: M Achebe, et al.
Published: (2022-01-01)

Promising role of voxelotor in managing sickle cell disease in children: a narrative review
by: Amit Agrawal, et al.
Published: (2025-02-01)

Effects of GBT1118, a voxelotor analog, on bone disease in sickle cell disease mice
by: Liping Xiao, et al.
Published: (2024-09-01)

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
by: Michael Migotsky, et al.
Published: (2022-09-01)

5610417 IN-VITRO REAL-TIME OBSERVATION OF MODERATE SICKLING KINETICS IN SICKLE ERYTHROCYTES TREATED BY VOXELOTOR UNDER MONOTONIC AND CYCLIC HYPOXIA
by: Y.Q. Qiang, et al.
Published: (2023-04-01)

Changes in indicators of cerebral metabolic stress following treatment with voxelotor in children and adolescents with sickle cell anemia
by: Andrew M. Heitzer, et al.
Published: (2024-10-01)

Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action
by: Michelle L. Green, et al.
Published: (2022-06-01)

S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)
by: Alan Anderson, et al.
Published: (2023-08-01)

REAL-WORLD DATA ON THE TREATMENT OF SICKLE CELL DISEASE WITH VOXELOTOR: RESULTS FROM A BRAZIL'S EARLY ACCESS PROGRAM
by: RD Cancado, et al.
Published: (2023-10-01)

S279: EFFECT OF VOXELOTOR ON CEREBRAL PERFUSION AND CEREBRAL OXYGEN METABOLISM IN ADULT PATIENTS WITH SICKLE CELL DISEASE; THE COVERAGE STUDY
by: Kadère Konté, et al.
Published: (2023-08-01)

Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease
by: Awni Alshurafa, et al.
Published: (2022-09-01)

Voxelotor improves red blood cell functionality in children with sickle cell anaemia: An ancillary study of the HOPE‐KIDS 1 trial
by: Satheesh Chonat, et al.
Published: (2024-02-01)

P-013: VOXELOTOR REDUCES SICKLE RED BLOOD CELL-MEDIATED HYPOXIC MICROVASCULAR OCCLUSION AS MEASURED BY OCCLUSIONCHIP IN VITRO MICROFLUIDIC ASSAY
by: SEKYONDA Z., et al.
Published: (2022-08-01)

W.J. Alberts, De stadsrekeningen van Arnhem, V, 1428-1432
by: J.A. Kossmann-Putto
Published: (1986-01-01)

1432 Cancer-associated fibroblasts metabolic targeting overcomes T-cell exclusion and chemoresistance
by: Emily Ko, et al.
Published: (2023-11-01)

P-059: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 RESOLVE TRIAL INVESTIGATING THE EFFICACY OF VOXELOTOR WITH STANDARD OF CARE IN THE RESOLUTION OF LEG ULCERS IN PATIENTS WITH SICKLE CELL DISEASE
by: MINNITI C., et al.
Published: (2022-08-01)

Frenemy: adaptive temperate phage_SAP_1432 supports Staphylococcus aureus survival in changing temperatures
by: Ting-ting Liu, et al.
Published: (2025-08-01)

Evidencias bioarqueológicas de conflicto ca. 1000-1432 AD en la Quebrada de Humahuaca y el Valle Calchaquí Bioarchaeological evidence of conflict in Quebrada de Humahuaca and Calchaquí Valley, ca. Ad 1000-1432
by: María Soledad Gheggi, et al.
Published: (2012-07-01)

Note sugli Alighieri di Verona (1355-1432) e aggiunte al Codice Diplomatico Dantesco
by: Claudio Bismara
Published: (2021-09-01)

P1439: EPELEUTON, A NOVEL SYNTHETIC Ω-3 FATTY ACID, REDUCES ENDOTHELIAL ADHESION OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS UNDER PHYSIOLOGICAL FLOW CONDITIONS
by: Moayed Hamza, et al.
Published: (2023-08-01)

Samuel Mareel, Voor Vorst en Stad. Rederijkersliteratuur en Vorstenfeest in Vlaanderen en Brabant (1432-1561)
by: Jelle Haemers
Published: (2011-09-01)

5613294 BASELINE PATIENT CHARACTERISTICS FROM A UK EARLY ACCESS TO MEDICINES SCHEME (EAMS) WITH VOXELOTOR, A HBS POLYMERIZATION INHIBITOR, FOR THE TREATMENT OF HEMOLYTIC ANEMIA DUE TO SICKLE CELL DISEASE
by: P. Eleftheriou, et al.
Published: (2023-04-01)

Paweł Włodkowic, Writings (1416–1432). The struggle for the Self-Determination of Central Europe, Rzym–Warszawa 2023, ss. 664
by: Michał Matusiak
Published: (2025-06-01)

Influence of Voxelotor–hemoglobin complexes in the estimation of hemoglobin S levels by the current standard of care laboratory evaluation techniques
by: Salam Alkindi, et al.
Published: (2023-04-01)

آراء فضل عباس (ت: 1432هـ) في نسخ التلاوة على ضوء عقيدة أهل السنة والجماعة (عرض ونقد)
by: آلاء بنت عبدالله بن حسين عجاج
Published: (2024-03-01)